Altimmune Past Earnings Performance

Past criteria checks 0/6

Altimmune's earnings have been declining at an average annual rate of -20.1%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been declining at an average rate of 48.8% per year.

Key information

-20.1%

Earnings growth rate

8.4%

EPS growth rate

Biotechs Industry Growth11.5%
Revenue growth rate-48.8%
Return on equity-77.6%
Net Margin-199,076.9%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Altimmune makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

LSE:0A4C Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 240-104200
30 Jun 240-101200
31 Mar 240-93190
31 Dec 230-88180
30 Sep 230-78180
30 Jun 230-81180
31 Mar 230-85170
31 Dec 220-85170
30 Sep 223-87170
30 Jun 223-97170
31 Mar 224-102160
31 Dec 214-97150
30 Sep 213-84160
30 Jun 216-68160
31 Mar 217-60150
31 Dec 208-49130
30 Sep 206-43110
30 Jun 204-3690
31 Mar 205-2290
31 Dec 196-2190
30 Sep 198-4290
30 Jun 1910-3490
31 Mar 1911-4090
31 Dec 1810-42100
30 Sep 1811-2990
30 Jun 1813-58100
31 Mar 1813-52100
31 Dec 1711-5180
30 Sep 179-4380
30 Jun 175-1680
31 Mar 173-1470
31 Dec 163-1160
30 Sep 163-1050
31 Dec 155-750
31 Dec 146-110

Quality Earnings: 0A4C is currently unprofitable.

Growing Profit Margin: 0A4C is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 0A4C is unprofitable, and losses have increased over the past 5 years at a rate of 20.1% per year.

Accelerating Growth: Unable to compare 0A4C's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 0A4C is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).


Return on Equity

High ROE: 0A4C has a negative Return on Equity (-77.61%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 11:52
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Altimmune, Inc. is covered by 12 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Mayank MamtaniB. Riley Securities, Inc.
Joshua SchimmerEvercore ISI
Liisa BaykoEvercore ISI